ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Response to entecavir treatment and evolution of HBV quasispecies in patients with failure to second line treatment with adefovir
Zeitschrift für Gastroenterologie
◽
10.1055/s-0032-1332138
◽
2013
◽
Vol 51
(01)
◽
Author(s):
A Herber
◽
K Deterding
◽
C Jochum
◽
B Kronenberger
◽
HH Feucht
◽
...
Keyword(s):
Line Treatment
◽
Second Line
Download Full-text
Related Documents
Cited By
References
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo
10.1055/s-0037-1605011
◽
2017
◽
Author(s):
P Galle
◽
P Merle
◽
A Granito
◽
YH Huang
◽
G Bodoky
◽
...
Keyword(s):
Hepatocellular Carcinoma
◽
Tumor Progression
◽
Phase Iii
◽
Line Treatment
◽
Second Line
Download Full-text
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature
Journal of Neurosurgical Sciences
◽
10.23736/s0390-5616.16.03874-1
◽
2019
◽
Vol 63
(4)
◽
Cited By ~ 7
Author(s):
Salvatore Grisanti
◽
Vittorio D. Ferrari
◽
Michela Buglione
◽
Giorgio M. Agazzi
◽
Roberto Liserre
◽
...
Keyword(s):
Systematic Review
◽
Phase Ii
◽
Phase Ii Study
◽
Recurrent Glioblastoma
◽
Line Treatment
◽
Second Line
◽
Review Of Literature
Download Full-text
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Case Medical Research
◽
10.31525/ct1-nct03959293
◽
2019
◽
Author(s):
Keyword(s):
Clinical Trial
◽
Line Treatment
◽
Second Line
Download Full-text
Avelumab + Paclitaxel/ Ramucirumab as Second Line Treatment in Gastro-esophageal Adenocarcinoma
Case Medical Research
◽
10.31525/ct1-nct03966118
◽
2019
◽
Author(s):
Keyword(s):
Esophageal Adenocarcinoma
◽
Line Treatment
◽
Second Line
Download Full-text
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
Case Medical Research
◽
10.31525/ct1-nct04010071
◽
2019
◽
Author(s):
Keyword(s):
Malignant Tumors
◽
Line Treatment
◽
Second Line
Download Full-text
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
Case Medical Research
◽
10.31525/ct1-nct04029350
◽
2019
◽
Author(s):
Keyword(s):
Stage Iiib
◽
Line Treatment
◽
Second Line
Download Full-text
Faculty Opinions recommendation of Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718047126.793482089
◽
2013
◽
Author(s):
Thomas Stinchcombe
Keyword(s):
Lung Cancer
◽
Randomised Controlled Trial
◽
Small Cell Lung Cancer
◽
Controlled Trial
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Wild Type
◽
Small Cell Lung
◽
Randomised Controlled
Download Full-text
Faculty Opinions recommendation of Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718451079.793497341
◽
2014
◽
Author(s):
Laurie Carr
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Disease Progression
◽
Stage Iv
◽
Small Cell
◽
Line Treatment
◽
Second Line
◽
Small Cell Lung
◽
Phase 3
◽
Double Blind
Download Full-text
Faculty Opinions recommendation of Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.725347054.793541339
◽
2018
◽
Author(s):
Ravindra Sarode
Keyword(s):
Immune Thrombocytopenia
◽
Controlled Trial
◽
Line Treatment
◽
Second Line
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Faculty Opinions recommendation of Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.725347054.793527308
◽
2017
◽
Author(s):
Aimee Payne
Keyword(s):
Immune Thrombocytopenia
◽
Controlled Trial
◽
Line Treatment
◽
Second Line
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close